MLCT Oil for Fatty Liver - PASS Trial

Inclusion Criteria: * Between 21 to 65 years old; * Body mass index (BMI) 23 kg/m2 or higher; * NAFLD or NASH as determined by liver biopsies within last 2 years with fibrosis stage F1-F4; OR Presence of steatosis and fibrosis via Transient Elastography / MRI * Participants willing and able to adhere to the prohibitions and restrictions specified in the protocol; * Participants willing and able to adhere to the dietary prescription as in the study protocol; * Participants willing and able to provide written informed consent. * Participants able to read and write English, and own a smartphone with a data plan Exclusion Criteria: * Poorly controlled diabetes * Poorly controlled hypertension * Estimated glomerular filtration rate of less than 60 ml/min/1.73m2; * Presence of active alcoholic liver disease, chronic viral hepatitis, drug-induced hepatitis; autoimmune hepatitis, and liver cancer; * A history of Type 1 diabetes mellitus or previous admission for diabetic ketoacidosis; * Recurrent urinary tract infection (2 or more over the past one year); * Having any medical condition that would affect metabolism (i.e. Cushing syndrome, known active hyperthyroidism or hypothyroidism); * Serious medical disease with likely life expectancy less than 5 years; * Recently started on selected diabetes / hypertensive medications. Must be on stable doses. * Ongoing eating disorder or significant weight loss or weight gain as defined by change of 5% or more within 12 weeks before screening visit; * History of any malignancy within 5 years of screening; * Women who are pregnant or plan to become pregnant; * Taking alcohol above the limit recommended (i.e. consumed more than 10 g/day for women or 20 g/day for men); * Participation in other clinical trial in the 30 days before randomization; * Participants who cannot be followed up for at least 6 weeks (due to health situation or travel); * Having allergies / intolerances to the ingredients in the prepared meals or oil-containing products of the study; * Having chronic gastrointestinal disorders; * Having taken antibiotics in the last 3 months; * Participants with arthropathy, CVM, CVA disorder or any systemic disorder which render or when intervention may be dangerous.